ArticleCancer2022
Pre- and on-treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non-small cell lung cancer.
Article in Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- The prognostic value of the lung immune prognostic index in patients with urological cancers: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Research progress on lactate metabolism in lung cancer: Tumorigenesis, drug resistance and clinical translation (Review).Oncology reports · 2026Review
- Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Article
- Review of Existing Approaches and Potential Role of Pharmacometrics in the Interpretation of Prognostic Circulating Serum Biomarkers in Advanced NSCLC.Clinical and translational science · 2026Review
- The prognostic significance of early changes in the lung immune prognostic index in patients treated with immunotherapy for advanced-stage lung cancer.Discover oncology · 2026Article
- Lactate Dehydrogenase as a Potential Mediator Between Immature Granulocytes and Tumor Burden in Breast Cancer.Journal of inflammation research · 2026Article
- An explainable nomogram incorporating systemic inflammatory indicators and radiation esophagitis for risk assessment of radiation pneumonitis in lung cancer.Frontiers in immunology · 2026Article
- Using Bayesian Networks to Predict Urgent Care Visits in Patients Receiving Systemic Therapy for Non-Small Cell Lung Cancer.JCO clinical cancer informatics · 2025Article
- Article
- Development of a Joint Tumor Size-Overall Survival Modeling and Simulation Framework Supporting Oncology Development Decision-Making.CPT: pharmacometrics & systems pharmacology · 2025Article
- Article
- Application of random survival forest to establish a nomogram combining clinlabomics-score and clinical data for predicting brain metastasis in primary lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- A Pilot Study on Qualitative Metabolomics to Characterize Lewis Lung Carcinoma in Mice.Life (Basel, Switzerland) · 2025Article
- Serum lactate dehydrogenase as a prognostic marker for treatment response in IDH wild-type glioblastoma patients undergoing stupp protocol.Journal of neuro-oncology · 2025Article
- Predictive Radiomics-Based Model for Recurrence-Free Survival After Curative Resection in Patients with Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2025Article
- Development and validation of a nomogram for predicting 90-day mortality in patients with advanced lung cancer based on inflammatory and nutritional biomarkers.American journal of cancer research · 2025Article
- First-line chemoimmunotherapy for patients with small-cell lung cancer and interstitial lung abnormality: CIP risk and prognostic analysis.Thoracic cancer · 2024Article
- Predictive value of inflammation and nutritional index in immunotherapy for stage IV non-small cell lung cancer and model construction.Scientific reports · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe survival outcomes of patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) are variable. This study investigated whether pre- and on-treatment lactate dehydrogenase (LDH) could better prognosticate and select patients for ICI therapy.
methodsUsing data from the POPLAR and OAK trials of atezolizumab versus docetaxel in previously treated advanced NSCLC, the authors assessed the prognostic and predictive value of pretreatment LDH (less than or equal to vs greater than the upper limit of normal). They further examined changes in on-treatment LDH by performing landmark analyses and estimated overall survival (OS) distributions according to the LDH level stratified by the response category (complete response [CR]/partial response [PR] vs stable disease [SD]). They repeated pretreatment analyses in subgroups defined by the programmed death ligand 1 (PD-L1) status.
resultsThis study included 1327 patients with available pretreatment LDH. Elevated pretreatment LDH was associated with an adverse prognosis regardless of treatment (hazard ratio [HR] for atezolizumab OS, 1.49; P = .0001; HR for docetaxel OS, 1.30; P = .004; P for treatment by LDH interaction = .28). Findings for elevated pretreatment LDH were similar for patients with positive PD-L1 expression treated with atezolizumab. Persistently elevated on-treatment LDH was associated with a 1.3- to 2.8-fold increased risk of death at weeks 6, 12, 18, and 24 regardless of treatment. Elevated LDH at 6 weeks was associated with significantly shorter OS regardless of radiological response (HR for CR/PR, 2.10; P = .04; HR for SD, 1.50; P < .01), with similar findings observed at 12 weeks.
conclusionsIn previously treated advanced NSCLC, elevated pretreatment LDH is an independent adverse prognostic marker. There is no evidence that pretreatment LDH predicts ICI benefit. Persistently elevated on-treatment LDH is associated with worse OS despite radiologic response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.